Physician profile
Christopher Morris
NPI 1033644612
$4,401.00
in general payments reported to CMS, 2019-2025
27 companies · $634 in 2025
The $634 reported for 2025 was more than what 92% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $192 · 2021: $625 · 2022: $979 · 2023: $992 · 2024: $979 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,605.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $914.61 | 2020-2025 | |
| Abbvie INC. | $714.91 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $458.36 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $417.26 | 2021-2025 | Zerbaxa, Dificid, Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.71 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $218.86 | 2020-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $213.85 | 2020-2024 | Lokelma |
| Gilead Sciences, INC. | $209.71 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.70 | 2020-2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $118.43 | 2023 | Myfembree, Gemtesa |
| Boston Scientific Corporation | $91.78 | 2020-2024 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $87.99 | 2021-2025 | Eliquis |
| Paratek Pharmaceuticals, INC. | $81.00 | 2022-2023 | Nuzyra |
| Alexion Pharmaceuticals, INC. | $59.88 | 2023-2025 | Ultomiris |
| Myovant Sciences INC. | $45.19 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $37.71 | 2023-2024 | Rybelsus, Ozempic |
| Philips North America LLC | $33.74 | 2021-2023 | |
| Aspira Women'S Health INC | $32.18 | 2024 | Ova1 |
| Gynesonics, INC. | $29.87 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Cvrx, INC. | $29.72 | 2022 | |
| Sk Life Science, INC. | $29.04 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.07 | 2025 | Lifevest |
| Cmp Pharma, INC. | $22.15 | 2021 | |
| Ambu INC. | $20.46 | 2025 | |
| Idorsia Pharmaceuticals US INC | $18.41 | 2023 | Quviviq |
| Melinta Therapeutics, LLC | $15.13 | 2022 | |
| Coopersurgical, INC. | $14.28 | 2024 | Endosee |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.